Contact

Toshiba America Medical Systems and Merge Healthcare Partner on  Cardiology and Hemodynamic Solutions Toshiba, hemo, Merge Hemo, cardio, cardiology, Merge Cardiology Merge Healthcare's Best in KLAS Merge Hemo™ and Merge Cardio™ and Toshiba's vascular x-ray systems offered as an enhanced solution

Toshiba America Medical Systems and Merge Healthcare Partner on Cardiology and Hemodynamic Solutions

Merge Healthcare’s Best in KLAS Merge Hemo™ and Merge Cardio™ and Toshiba’s vascular x-ray systems offered as an enhanced solution

Merge Healthcare Incorporated (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that it has entered into a strategic partnership with Toshiba America Medical Systems, Inc. Under this new agreement, Toshiba will be able to offer its customers a full turnkey solution, combining Merge’s cardiology PACS and hemodynamic monitoring solutions with the Toshiba portfolio of vascular x-ray systems.

“At Toshiba, we understand our customers’ concerns when it comes to integrating IT solutions with imaging,” said Satrajit Misra, vice president, marketing, Toshiba America Medical Systems.  “Through this partnership, our customers will get a complete solution for accessing imaging information faster to improve the patient experience and our customers’ overall business.”

 Toshiba will leverage Merge’s Best in KLAS Merge Hemo™, Merge’s real-time documentation tool for the cardiac cath lab that facilitates the integration of cath lab documentation into the patient’s electronic health record, and Merge Cardio™, Merge’s web-enabled enterprise-level image and information system that provides a single point of entry to the patient’s complete cardio record spanning all cardiac modalities.

“For more than 15 years, the Toshiba Corporation has been a great partner with Merge and we are pleased to expand our partnership with Toshiba America Medical Systems to support their enterprise imaging initiative for a unified, interoperable cardiology management system,” said Justin Dearborn, chief executive officer at Merge Healthcare. “Being an enterprise imaging preferred partner is an honor, and we look forward to helping them achieve their objectives.”

About Toshiba American Medical Systems
With headquarters in Tustin, Calif., Toshiba America Medical Systems, Inc. markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corporation, an independent group company of Toshiba Corporation, is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems, as well as cardiac cath and EP labs. Toshiba Corporation is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 172,000 employees worldwide and annual sales of $54 billion. For more information, visit www.medical.toshiba.com.
 

About Merge
Merge is a leading provider of innovative enterprise imaging, interoperability and clinical systems that seek to advance healthcare. Merge’s enterprise and cloud-based technologies for image intensive specialties provide access to any image, anywhere, any time. Merge also provides clinical trials software with end-to-end study support in a single platform and other intelligent health data and analytics solutions. With solutions that have been used by providers for more than 25 years, Merge is helping to reduce costs, improve efficiencies and enhance the quality of healthcare worldwide. For more information, visit merge.com and follow us @MergeHealthcare.

Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.
 

Contact:
Michael R. Klozotsky
Vice President, Corporate Marketing
312.946.2535
michael.klozotsky@merge.com

 Download this press release >>

© 2017 IBM Watson Health. All Rights Reserved. Privacy | Terms | Email Signup | Sitemap